4.1 Article

Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery

期刊

JOURNAL OF CLINICAL PHARMACOLOGY
卷 45, 期 6, 页码 659-665

出版社

SAGE PUBLICATIONS INC
DOI: 10.1177/0091270005276117

关键词

ertapenem; pharmacokinetics; plasma; lung tissue; ELF; alveolar cells; CAP

向作者/读者索取更多资源

Ertapenem is approved for the treatment of community-acquired pneumonia ( CAP), but its in vivo penetration into lung tissue ( LT), epithelial lining fluid ( ELF), and alveolar cells ( AC) is unknown. Fifteen patients undergoing thoracotomy were treated with 1 g intravenously for perioperative prophylaxis. Bronchoalveolar lavage was performed 1, 3, and 5 hours after ertapenem infusion. Normal LT was sampled at the time of lung extraction. Blood was collected before and at different time points up to 24 hours after infusion. Mean concentrations of ertapenem in plasma, ELF, and AC were at 1.0 hour, 63.1, 4.06, 0.004 mg/L; at 3.0 hours, 39.7, 2.59, 0.003 mg/L; and at 5.0 hours, 27.2, 2.83, 0.007 mg/L. Mean ( range) concentration in LT was 7.60 ( 2.5 - 19.4) mg/kg tissue 1.5 to 4.5 hours after infusion. In plasma, ertapenem exhibited a C-max of 94.7 +/- 23.3 mg/L and an AUC(0-last) of 501.1 +/- 266.3 mg.h/ L. These results, combined with the reported ( MIC) 90 of most CAP bacteria, support the previously observed clinical efficacy of ertapenem in the treatment of CAP.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据